A small absorption signal
In five healthy men, DHB produced higher measured berberine exposure than a larger dose of standard berberine during a two-hour test window.
A four-dose protocol, not a single-dose efficacy trial. [1]
DIHYDROBERBERINE · HUMAN ORAL RESEARCH
Dihydroberberine.
Better exposure.
What comes next?
Small human studies suggest DHB can increase measured berberine exposure. That is an interesting first step. It is not yet proof of better blood sugar, weight loss or fewer digestive side effects.
Explore the findingsIngredient and research-formulation evidence. None of the cited studies tested a finished Neurogan product.
01 / WHAT THE EVIDENCE MEANS
More in the blood is not
the same as more benefit.
Dihydroberberine, or DHB, is a reduced form of berberine. After oral use, researchers can measure berberine and related metabolites in blood. That is an exposure question, not yet an answer about long-term health.
No clear glucose or insulin benefit
The same pilot did not find significant treatment differences in glucose or insulin responses to the test meal.
Too small and short to settle long-term efficacy. [1]
Better health outcomes?
The retrieved published human studies do not establish sustained improvements in HbA1c, weight or cholesterol from DHB.
Newer registered trials describe questions to test, not completed evidence of benefit. [3] [4]
02 / THE MEASURED EXPOSURE
A promising pharmacokinetic signal.
Pharmacokinetics describes what happens to an ingredient in the body. Here, the measured compound was berberine in plasma after people swallowed DHB or berberine.
Berberine exposure across the 0 to 120-minute window
Standard deviations, respectively: 16.2, 17.6, 115.9 and 694. Large variation in the 200 mg DHB condition makes its mean particularly uncertain. Berberine was already present at the first blood draw after earlier dosing. The bars are not baseline-corrected or dose-normalized.
The important companion result: glucose AUC did not differ significantly across treatments (p = 0.92), nor did insulin AUC (p = 0.22). Higher exposure cannot be relabeled as greater metabolic efficacy. [1]
Exact values, statistical limits & timing
| Treatment per dose | Berberine AUC, mean ± SD | Peak berberine, mean ± SD |
|---|---|---|
| Placebo | 20.2 ± 16.2 ng·min/mL | 0.22 ± 0.18 ng/mL |
| Berberine 500 mg | 42.3 ± 17.6 ng·min/mL | 0.40 ± 0.17 ng/mL |
| DHB 100 mg | 284.2 ± 115.9 ng·min/mL | 3.8 ± 1.4 ng/mL |
| DHB 200 mg | 929 ± 694 ng·min/mL | 12.0 ± 10.1 ng/mL |
These are Table 5 values. The paper labels the AUC unit “ng/mL × 120 min”; here it is expressed conventionally as ng·min/mL over the stated interval. The overall AUC comparison was significant (p = 0.045), but the overall peak-concentration comparison was not (p = 0.06). The AUC difference between DHB doses did not reach conventional significance.
The abstract and Results section differ slightly in a reported mean and pairwise p-values. The chart uses Table 5, rather than combining versions. The paper also differs on exact timing of the final dose relative to the meal and baseline draw. The 0 to 120-minute labels are the reported sampling window, not a precise single-dose absorption curve.
03 / THE STUDY CLOCK
Hours of observation.
Not months of treatment.
This is the sequence used in the five-person pilot. The timeline shows the experimental protocol, not a promised time to a health benefit. [1]
DAY BEFORE TESTING
Three assigned doses
One dose with each main meal, followed by an overnight fast.
TEST VISIT
Fourth dose and test meal
A standardized carbohydrate meal was used to examine glucose and insulin responses.
REPORTED BLOOD DRAWS
0 to 120 minutes
Samples at 0, 20, 40, 60, 90 and 120 minutes. Each person completed all four conditions with at least 72 hours between visits.
Repeated dosing before the first sample means “baseline” was not an untreated baseline. No synthetic glucose improvement curve is shown.
04 / THE PUBLISHED HUMAN STUDIES
Two small studies.
Different questions and formulas.
Direct oral DHB evidence should be read separately from ordinary berberine trials, cell experiments and supplier claims.
Four conditions, five healthy men
What happened
Plasma berberine exposure was higher after 100 mg or 200 mg DHB per dose than after 500 mg berberine per dose. Blood-glucose and insulin AUC differences were not significant.
What to keep in mind
There was no long-term treatment period, no HbA1c outcome and no diabetes population. Two high values strongly influenced the 200 mg result. This is not evidence for replacing a diabetes medicine or matching a clinical berberine dose.
Study details, safety & source access
Interventions: Glucovantage DHB manufactured by NNB Nutrition, standard berberine hydrochloride and resistant-dextrin placebo. All participants completed all four conditions; the trial was retrospectively registered.
Safety: 11 adverse events were reported across conditions by two participants. Six events were reported in the 100 mg DHB condition, one in the 200 mg condition, one with berberine and three with placebo. Most were mild; one was moderate. Events are not the same as people, and the sample is too small to establish fewer digestive problems.
Funding and access: NNB Nutrition funded the trial; an author was a paid adviser. Primary full text, Tables 3 to 5, methods and limitations reviewed. The exact timing and abstract/table inconsistencies are described beside the chart.
Read the source [1]
DHB versus a micellar berberine formula
What happened
The formulations produced different metabolite profiles. Berberine AUC over 24 hours averaged 41.1 ± 7.0 ng·h/mL with DHB and 26.0 ± 14.2 with micellar berberine (mean ± SEM). The berberine AUC difference was not statistically significant.
What to keep in mind
The DHB capsule also contained black pepper extract. There was no ordinary-berberine arm or placebo and no test of lasting glucose or lipid efficacy. This is not a clean comparison of isolated DHB against standard berberine.
Study details, safety & source access
Test preparations: the methods describe a capsule containing 100 mg DHB plus 5 mg black pepper extract, compared with a LipoMicel capsule containing 250 mg berberine hydrochloride. No Neurogan product was used. Eleven blood samples were collected, including baseline and 24 hours.
Other findings: selected metabolite AUCs differed significantly. A higher proportion remaining as unmetabolized berberine with the micellar formula is not itself a demonstrated health advantage. The companion Caco-2 experiment used cells, not people.
Safety and access: no adverse events were reported during the short observation period. Primary full text and Tables 1 to 2 reviewed. Several authors were Isura employees; a coauthor owned the Factors Group, associated with the micellar product. Larger independent clinical trials are needed.
Read the source [2]
05 / WHAT LONGER TRIALS NEED TO ANSWER
The next step is clinical benefit.
Registrations show what researchers intend to measure. They are not results, even if an estimated completion date has passed.
REGISTERED · NO RESULTS POSTED
Prediabetes, GLP-1 and glucose
NCT07210684 describes an estimated 54 participants and six weeks of DHB 400 mg/day versus placebo. Measures include meal-related GLP-1 and glucose responses, continuous glucose monitoring and appetite.
The record also describes an acute 200 mg test. No results were posted at the registry check. An intended GLP-1 measurement is not evidence that DHB works like a GLP-1 medicine. [3]
REGISTERED · NO RESULTS POSTED
Body composition and metabolic health
NCT07322679 describes an estimated 120 adults with overweight or mild obesity, DHB 400 mg/day versus placebo, and 12 weeks of treatment. Planned outcomes include body weight and waist circumference.
No results were posted at the registry check. Planned sample sizes and durations are not completed efficacy findings. [4]
Ordinary berberine reviews help explain the research interest, but they do not provide an effect size for DHB. For the separate berberine literature, read the berberine evidence page. [5]
06 / FROM RESEARCH TO PRODUCT
A different dose is not
a proven equivalent.
None of the cited studies tested Neurogan Health Dihydroberberine Capsules.
Neurogan Health Dihydroberberine Capsules
The live Supplement Facts image lists 250 mg dihydroberberine per one-capsule serving, with 60 servings per bottle. The listed other ingredient is vegetable cellulose capsule.
The product record directs one capsule daily, ideally 20 to 30 minutes before a meal, or as directed by a healthcare provider. That once-daily 250 mg protocol was not tested in either published pilot described here.
| Question | What was studied | What remains unknown |
|---|---|---|
| Same amount? | 100 or 200 mg per dose in a four-dose pilot; a 100 mg DHB capsule with black pepper in the 24-hour pilot. | The Neurogan 250 mg once-daily regimen is different. A larger dose does not establish a larger benefit. |
| Same formulation? | Named research preparations, including Glucovantage and a DHB + black pepper capsule. | The displayed Neurogan label does not establish supplier identity or equivalence to those preparations. Black pepper is not listed. |
| Equivalent to berberine? | Small studies measured blood concentrations, not clinical dose equivalence. | No validated conversion turns 250 mg DHB into a specific clinically equivalent berberine dose. |
| Fewer side effects? | Very small, brief adverse-event observations. | The evidence does not establish fewer gastrointestinal complaints or superior long-term safety. |
07 / SAFETY & OPEN QUESTIONS
Less evidence requires more caution.
Higher exposure is a reason to study safety and interactions carefully, not a reason to assume they disappear.
What has actually been observed?
The five-person pilot reported mostly mild events across conditions. The nine-person study reported none during 24 hours. Neither could detect uncommon harms or establish months-to-years safety. The published evidence does not support a reliable side-effect advantage over berberine. [1] [2]
Drug interactions are unresolved
DHB raises measured berberine exposure, but dedicated clinical interaction studies are lacking in this evidence set. If you use diabetes medicines, transplant drugs or other prescriptions, review DHB with your clinician or pharmacist before use.
Pregnancy, breastfeeding and children
Direct DHB safety evidence in these groups is missing. Berberine has important pregnancy, nursing and infant cautions. Because DHB produces berberine exposure, avoid treating it as a safer workaround; seek qualified medical advice. [6]
What would change confidence?
Larger, longer placebo-controlled trials of a clearly characterized DHB product, with measured glucose or lipid outcomes, systematic adverse-event tracking and clinically relevant populations. Exposure studies alone cannot fill that gap.
THE TAKEAWAY
Promising delivery research.
Clinical benefits still to prove.
DHB is worth investigating because it changes berberine exposure. Whether that translates to lasting benefits, a useful dose or better tolerability is a separate question.
Read the original research ↓08 / SOURCES & FURTHER READING
Follow each finding to its source.
A focused human oral evidence review, not a systematic review. Literature and live product records checked September 10, 2026. Reviews overlap with individual trials and are not counted as new participants.
- PRIMARY FULL TEXT
Moon et al. Absorption kinetics of berberine and dihydroberberine
Nutrients 14(1):124. Published online December 2021, 2022 volume. PMID 35010998. DOI 10.3390/nu14010124. Chart: Table 5 AUC; Tables 3 and 4 provide safety and time-point context.
Read the source ↗ - PRIMARY FULL TEXT
Chang et al. Differences in metabolite profiles of DHB and micellar berberine
International Journal of Molecular Sciences, 2024. PMID 38891813. DOI 10.3390/ijms25115625. Human oral pilot and separate Caco-2 experiments. Methods 4.1, Tables 1 and 2.
Read the source ↗ - REGISTRY · NOT RESULTS
NCT07210684: DHB in adults with prediabetes
Six-week registered study. Registry API checked September 10, 2026: no results posted. Enrollment is an estimate, not a completed analysis.
Read the source ↗ - REGISTRY · NOT RESULTS
NCT07322679: DHB, body composition and metabolic health
Twelve-week registered study. Registry API checked September 10, 2026: no results posted. Planned clinical outcomes do not establish benefit.
Read the source ↗ - CONTEXT REVIEW · BERBERINE, NOT DHB
Blais et al. Berberine for dyslipidemia in adults
2023 systematic review. PMID 36941490. Ordinary berberine trials provide context only, not transferable DHB efficacy. Abstract reviewed.
Read the source ↗ - SAFETY CONTEXT · BERBERINE
NCCIH: Berberine and weight loss
Berberine safety and interaction guidance. This is not a DHB-specific safety trial; the distinction matters when considering a related ingredient.
Read the source ↗